Noteworthy

Feb 01, 2012
Pharmaceutical Executive
For a rendering to be effective, the right balance must be struck between captivating art and accurate science.
Jan 01, 2012
From Pharmaceutical Technology Europe
The next two years may see a shake up in the world's current top pharmaceutical companies, with Pfizer likely to be the only US firm to remain in the top five by sales.
Jan 01, 2012
Pharmaceutical Executive
Pharma has become unusually quick to strike embrace the iPad. But the industry's inherent conservatism means it has some way to go to fully milk the device's potential.
Jan 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all?
Jan 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Jan 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Mason Tenaglia offers empirical defense of coupons and copay offset programs.
Jan 01, 2012
Pharmaceutical Executive
A selection of the recent breakthrough technologies showcased at the Cleveland Clinic's Medical Innovations Summit.
Jan 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
William Looney looks at how Big Pharma is attempting to bridge the emerging markets' widening cancer divide.
Jan 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Pharma must coordinate the efforts of medical, legal, HR, global partners and many other players in the regulatory compliance space to keep itself afloat in choppy seas.
Dec 01, 2011
From Pharmaceutical Technology Europe
By Pharmaceutical Executive Editors
The economic and financial crisis rumbles on, but data from Pharmaceutical Technology's 2011 annual employment survey shows a positive outlook for 2012.
native1_300x100
lorem ipsum